- CEO
- Zhiping Mao
- Full Time Employees
- 2,297
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- No. 999 Fushan Road Nanchang JX China 330200
- IPO Date
- May 5, 2015
- Business
- Jiangxi Sanxin Medtec Co., Ltd. (300453.SZ) develops, manufactures, and sells medical devices with a focus on blood purification solutions; it offers core products including dialysate filters, dialysis indwelling needles, hemodialysis machines, centralized dialysate supply systems, hemodialysis water preparation systems, hollow fiber hemodialyzers, sterile hemodialysis blood circuits, tubing sets for hemodialysis, hemodialysis powders and concentrates, arteriovenous spikes, and nursing kits for dialysis; infusion and transfusion sets such as light-resistant infusion sets, TPE precise filter infusion sets, auto-stop fluid precise filter infusion sets, catheter infusion sets, and transfusion sets; indwelling catheters comprising straight, Y-type, closed, and positive pressure IV catheters, central venous catheter packs, extension tubes with three-way valves, and heparin caps; injection devices including insulin, dispenser, sterile, auto-disable syringes, fixed-dose immunization syringes, hypodermic needles, needleless injection systems, and pneumatic syringes; cardiothoracic surgery products such as blood microembolus filters, disposable extracorporeal circulation tubing kits, cold cardioplegic solution perfusion apparatus, and blood containers; as well as protective items like medical surgical face masks, disinfectants, and alcohol pads. Founded in 1997 and headquartered in Nanchang, Jiangxi Province, China, at No. 999 Fushan Avenue, Xiaolan Economic Development Zone, the company operates eight intelligent production bases and serves markets in over 100 countries and regions, holding more than 200 patents, over 100 product registrations, and participation in 10 national and industry standards; it has obtained CE, CMD, and US FDA 510K certifications. In recent developments, the company received approval in 2025 for China's first domestically-produced hemodialysis concentrates containing citric acid and a catheter flush device; it launched needle-free syringes for diabetes management and advanced early chronic kidney disease solutions via subsidiary Shengdankan, including a colon dialysis machine and sterile rectal catheters; additionally, it showcased innovations in hemodialysis, infusion therapy, diabetes management, and vascular access at CMEF 2025 and reported semi-annual revenue of 400.23 million CNY with net income of 67.81 million CNY in 2025.